Synendos Therapeutics AG

Synendos Therapeutics AG is excited to announce the publication of the latest article written by Andrea Chicca and Jürg Gertsch, “CNS Drug Discovery in Academia: Where Basic Research Meets Innovation“, now available on #ChemBioChem: https://lnkd.in/eZ4mcQ7D In this article, they provide their perspective on the interaction between academia and drug discovery based on a 12-year experience with the NCCR-TransCure project, from which Synendos Therapeutics AG originated. Read the full article and discover how innovative research in academia can inspire drug discovery. #Biotech #Academia #drugdiscovery #ChemBioChem #SERI #endocannabinoidsystem

Synendos Therapeutics AG is delighted to welcome Renata Lazarova, M.D. as our new Head of Clinical Development. Renata brings wealth of experience and a passion for therapy development and patient engagement. We are confident that her expertise and leadership will be a great asset to our team. A warm welcome from the entire team, Renata! #Neuroscience #Biotech #endocannabinoidsystem #clinicaldevelopment

Follow and support our progress in driving transformation in mental health care! Synendos Therapeutics AG is excited to be part of the TOP100 Swiss Start-up Award Public Voting 2024! You can vote to help us on our journey: 1. Visit our startup.ch profile: https://lnkd.in/eWWDzwkC 2. Click on the “Vote Now” button using your LinkedIn profile Together, we will drive innovation in neuroscience and mental health care needs! #TOP100SSU #MentalHealth #BiotechInnovation #SwissStartups #endocannabinoidsystem #neuropsychiatry #SERI

Synendos Therapeutics AG is excited to attend the 2024 BIO International Conference held in San Diego, 3rd-6th June 2024. Please join us and meet our CEO Andrea Chicca and CCO Simon Russell to hear about the latest advances of our clinical stage neuroscience company. #BIO2024 #healthcare #biotech #SERI #endocannabinoidsystem #neuroscience

Synendos Therapeutics AG is presenting at the Bio€quity Europe Conference in San Sebastian. Meet our CEO&CSO Andrea Chicca for a talk on Monday the 13th of May 2024 at 15h30. #BioEquityEurope #healthcare #biotech #SERI #endocannabinoidsystem

Synendos Therapeutics AG is participating in the Bio€quity Europe Conference in San Sebastian. Meet our CEO Andrea Chicca and CCO Simon Russell from the 12th to the 14th of May 2024. #BioEquityEurope #healthcare #biotech #SERI #endocannabinoidsystem 

Synendos Therapeutics AG’ CEO & CSO Andrea Chicca will join a roundtable on overcoming obstacles and seizing opportunities in early phase biotech research at the Swiss Biotech Day conference on Monday the 22nd at 12h. #swissbiotechday #healthcare #SERI #endocannabinoidsystem #biotech

Please join Synendos Therapeutics AG’ CCO and cofounder Simon Russell in a panel session on recent trends in biopharma innovation in investment and dealmaking at the Swiss Biotech Day conference on Tuesday the 23rd at 15h. #swissbiotechday #healthcare #SERI #endocannabinoidsystem #biotech

Join Synendos Therapeutics AG at the Swiss Biotech Day where Andrea Chicca CEO/CSO and Simon Russell CCO will attend the Conference in Basel from 22-23 April 2024. #swissbiotechday #healthcare #SERI #endocannabinoidsystem #biotech

Our CEO, Andrea Chicca, spoke to Scrip about his predictions of therapeutic area advances in 2024 – the interest in neuroscience is likely to continue.    2023 saw a resurgence of interest in neuroscience – for example, the filing of the first new potential treatment for schizophrenia in decades. This milestone leads the way together with other positive clinical data in neuropsychiatric disorders such as PTSD and provides an important inspiration for companies like Synendos Therapeutics AG.   Read more: https://bit.ly/3I042Uv   #ScripAsks2024 #neuroscience #endocannabinoidsystem